Stealth BioTherapeutics MMPOWER-2 and REPOWER Study Update
Stealth BioTherapeutics patient/community update on MMPOWER-2 and RePOWER Primary Mitochondrial Myopathy clinical trials
Stealth’s CEO Reenie McCarthy and Chief Clinical Development Officer Jim Carr shares updates on Stealth’s second clinical trial for mitochondrial myopathy, the MMPOWER-2 study.
Join us for this free webinar to learn more about:
Safety and tolerability data of elamipretide (previously known as Bendavia) from the MMPOWER-2 study
Tests and assessments used to measure efficacy of elamipretide in the MMPOWER-2 trial
Endpoints and outcomes from the MMPOWER-2 trial for people ages 16-65 with genetically-confirmed mitochondrial myopathy
Future Stealth BT studies evaluating elamipretide and mitochondrial myopathy
All are welcome and encouraged to listen to this live presentation. An opportunity to submit questions online will be provided during the live webinar.